Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Connect with us

Hi, what are you looking for?

slide 3 of 2
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Not Sure

Not Sure

The FDA Proposes New Rules for Opioids to Make Drugs Less Addictive

opioid drugs
opioid drugs

Listen to the article now

The Food and Drug Administration (FDA) is looking into changing the rules for the manufacturing of opioids by making the drugs less addictive.

The new proposal states that the drug manufacturers would have to report if their products have “any characteristics that would mitigate the risks of overdose, abuse, or the development of addiction.”

The FDA also said: “Companies should also indicate whether their drugs have novel or greater risks compared to other opioids on the market and also note the public health implications of their products in terms of risks to non-patients, including members of the patient’s household, visiting relatives, friends, and others.”

According to the data from the U.S. Centers for Disease Control and Prevention, 47,000 people died from a drug overdose in 2017, with approximately 130 individuals overdosing every day. The Trump administration considers this to be a significant problem and has promised to crack down on illicit drug use.

Acting FDA Commissioner, Ned Sharpless, made a statement: “Addressing the crisis of opioid addiction is an issue of great concern for our nation and remains a top public health priority for the FDA. The agency continues to take new steps to confront this crisis while also paying careful attention to the needs of patients in accessing appropriate pain management.”

The FDA has admitted that opioids are challenging since the drugs help patients with pain management, but that they can also cause immense harm if misused or abused.

Related: Demi Lovato Wakes Up After Drug Over Dose


Comment Template

You May Also Like

Health

New York Governor Kathy Hochul refuses to extradite Dr. Margaret Carpenter to Louisiana for prescribing abortion pills, sparking a legal showdown over state sovereignty...

Politics

President Donald Trump's new tariffs on Canada, Mexico, and China aim to bolster U.S. industries but risk driving up consumer costs, destabilizing global trade,...

Health

The U.S. healthcare sector, undervalued and facing reduced regulatory scrutiny under Trump’s administration, is poised for a strong rebound in 2025. Key growth areas...

Business

On Monday, contract drugmaker Catalent Inc. (CTLT.N) said it expected to “significantly” lower its 2023 sales and core profit expectations and delay its third-quarter...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok